Lung Cancer in 2022 and Beyond
Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment. Topics include clinical decision-making, the extent emerging data will affect ongoing research, development of new compounds, and future treatment paradigms.
FACULTY CHAIR
Corey Langer, MD, FACP
University of Pennsylvania, PA, USA
Faculty Members
Shirish Gadgeel, MD
Henry Ford Health, Detroit, MI, USA
Paul Bunn, MD, FASCO
University of Colorado School of Medicine, Aurora, CO, USA
Martin Edelman, MD
Fox Chase Cancer Center, Philadelphia, PA ,USA
Antoinette Wozniak, MD, FACP, FASCO
UPMC Hillman Cancer Center, Pittsburgh, PA, USA
Ignacio I. Wistuba, MD
MD Anderson Cancer Center, Houston, TX, USA
Roy Herbst, MD, PhD
Yale Cancer Center, New Haven, CT, USA
Natasha Leighl, MD, FASCO
University of Toronto, Ontario, Canada
Paul Paik, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Jamie Chaft, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Fred Hirsch, MD, PhD
The Tisch Cancer Institute, New York, NY, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Prognostic and Predictive Biomarkers in NSCLC: Pathologic Implications, Clinical and Research Relevance
- New Directions for EGFR-Mutant NSCLC
- EGFR (Less Common Mutations, Including Exon 20 Insertions)
- Emergence of Immunotherapy and Bispecifics in SCLC
- Therapeutic Landscape for Fusion-Positive NSCLC (ALK, ROS1, NTRK, RET)
- Inhibiting Oncogenic Mutations: Overcoming Mutant KRAS, HER2, MET, and BRAF
- Promising New Targets/Agents in Lung Cancer: ADCs and Beyond
- Perioperative Immunotherapy in Early NSCLC
- Immunotherapy in Unresectable Stage III NSCLC
- First-Line Immunotherapy in Metastatic NSCLC: Single Agent or Combination?
- New Directions for Second-Line Therapy
- Emergence of Immunotherapy and New Agents in SCLC
